Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab

L. C. Olmos, M. S. Sayed, A. L. Moraczewski, Steven J Gedde, Philip J Rosenfeld, W. Shi, William J Feuer, Richard K Lee

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Aims: To compare the outcomes of neovascular glaucoma (NVG) treated with and without intravitreal bevacizumab in a large case comparison study. Methods: The study is a retrospective, comparative, case series of 163 eyes of 151 patients with NVG, including 99 treated without and 64 treated with intravitreal bevacizumab. Medical and surgical treatments for NVG were assessed. The main outcome measures were visual acuity (VA) and intraocular pressure (IOP). Results: At the time of NVG diagnosis, the median VA was count fingers (CF) in the non-bevacizumab group and 2/300 in the bevacizumab group. IOP (mean±SD) was 43.1±13.0 mm Hg in the non-bevacizumab group and 40.8±11.5 mm Hg in the bevacizumab group. IOP (mean±SD) decreased to 18.3±13.8 mm Hg in the non-bevacizumab group and 15.3±8.0 mm Hg in the bevacizumab group, and the median VA was CF in both treatment groups at a mean follow-up of 12 months. Panretinal photocoagulation (PRP) substantially reduced the need for glaucoma surgery (P

Original languageEnglish (US)
Pages (from-to)463-472
Number of pages10
JournalEye (Basingstoke)
Volume30
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Neovascular Glaucoma
Intraocular Pressure
Visual Acuity
Fingers
Light Coagulation
Glaucoma
Case-Control Studies
Outcome Assessment (Health Care)
Bevacizumab
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab. / Olmos, L. C.; Sayed, M. S.; Moraczewski, A. L.; Gedde, Steven J; Rosenfeld, Philip J; Shi, W.; Feuer, William J; Lee, Richard K.

In: Eye (Basingstoke), Vol. 30, No. 3, 01.03.2016, p. 463-472.

Research output: Contribution to journalArticle

Olmos, L. C. ; Sayed, M. S. ; Moraczewski, A. L. ; Gedde, Steven J ; Rosenfeld, Philip J ; Shi, W. ; Feuer, William J ; Lee, Richard K. / Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab. In: Eye (Basingstoke). 2016 ; Vol. 30, No. 3. pp. 463-472.
@article{12d2f2e0bc7f4f0eb5104aeb902ec08b,
title = "Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab",
abstract = "Aims: To compare the outcomes of neovascular glaucoma (NVG) treated with and without intravitreal bevacizumab in a large case comparison study. Methods: The study is a retrospective, comparative, case series of 163 eyes of 151 patients with NVG, including 99 treated without and 64 treated with intravitreal bevacizumab. Medical and surgical treatments for NVG were assessed. The main outcome measures were visual acuity (VA) and intraocular pressure (IOP). Results: At the time of NVG diagnosis, the median VA was count fingers (CF) in the non-bevacizumab group and 2/300 in the bevacizumab group. IOP (mean±SD) was 43.1±13.0 mm Hg in the non-bevacizumab group and 40.8±11.5 mm Hg in the bevacizumab group. IOP (mean±SD) decreased to 18.3±13.8 mm Hg in the non-bevacizumab group and 15.3±8.0 mm Hg in the bevacizumab group, and the median VA was CF in both treatment groups at a mean follow-up of 12 months. Panretinal photocoagulation (PRP) substantially reduced the need for glaucoma surgery (P",
author = "Olmos, {L. C.} and Sayed, {M. S.} and Moraczewski, {A. L.} and Gedde, {Steven J} and Rosenfeld, {Philip J} and W. Shi and Feuer, {William J} and Lee, {Richard K}",
year = "2016",
month = "3",
day = "1",
doi = "10.1038/eye.2015.259",
language = "English (US)",
volume = "30",
pages = "463--472",
journal = "Eye (Basingstoke)",
issn = "0950-222X",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab

AU - Olmos, L. C.

AU - Sayed, M. S.

AU - Moraczewski, A. L.

AU - Gedde, Steven J

AU - Rosenfeld, Philip J

AU - Shi, W.

AU - Feuer, William J

AU - Lee, Richard K

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Aims: To compare the outcomes of neovascular glaucoma (NVG) treated with and without intravitreal bevacizumab in a large case comparison study. Methods: The study is a retrospective, comparative, case series of 163 eyes of 151 patients with NVG, including 99 treated without and 64 treated with intravitreal bevacizumab. Medical and surgical treatments for NVG were assessed. The main outcome measures were visual acuity (VA) and intraocular pressure (IOP). Results: At the time of NVG diagnosis, the median VA was count fingers (CF) in the non-bevacizumab group and 2/300 in the bevacizumab group. IOP (mean±SD) was 43.1±13.0 mm Hg in the non-bevacizumab group and 40.8±11.5 mm Hg in the bevacizumab group. IOP (mean±SD) decreased to 18.3±13.8 mm Hg in the non-bevacizumab group and 15.3±8.0 mm Hg in the bevacizumab group, and the median VA was CF in both treatment groups at a mean follow-up of 12 months. Panretinal photocoagulation (PRP) substantially reduced the need for glaucoma surgery (P

AB - Aims: To compare the outcomes of neovascular glaucoma (NVG) treated with and without intravitreal bevacizumab in a large case comparison study. Methods: The study is a retrospective, comparative, case series of 163 eyes of 151 patients with NVG, including 99 treated without and 64 treated with intravitreal bevacizumab. Medical and surgical treatments for NVG were assessed. The main outcome measures were visual acuity (VA) and intraocular pressure (IOP). Results: At the time of NVG diagnosis, the median VA was count fingers (CF) in the non-bevacizumab group and 2/300 in the bevacizumab group. IOP (mean±SD) was 43.1±13.0 mm Hg in the non-bevacizumab group and 40.8±11.5 mm Hg in the bevacizumab group. IOP (mean±SD) decreased to 18.3±13.8 mm Hg in the non-bevacizumab group and 15.3±8.0 mm Hg in the bevacizumab group, and the median VA was CF in both treatment groups at a mean follow-up of 12 months. Panretinal photocoagulation (PRP) substantially reduced the need for glaucoma surgery (P

UR - http://www.scopus.com/inward/record.url?scp=84960458330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960458330&partnerID=8YFLogxK

U2 - 10.1038/eye.2015.259

DO - 10.1038/eye.2015.259

M3 - Article

VL - 30

SP - 463

EP - 472

JO - Eye (Basingstoke)

JF - Eye (Basingstoke)

SN - 0950-222X

IS - 3

ER -